Gene therapy for renal disorders

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 919-926

  Lien, Yeong Hau H ^a   Lai, Li Wen ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute tubular necrosis; Gene therapy; Glomerulonephritis; Hereditary renal diseases; Kidney transplantation; Tubulointerstitial fibrosis

Indexed keywords

ALPHA GALACTOSIDASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTISENSE OLIGONUCLEOTIDE; ARACHIDONATE 15 LIPOXYGENASE; CHEMOKINE RECEPTOR CCR2; COMPLEMENTARY DNA; CONTRAST MEDIUM; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECORIN; EARLY GROWTH RESPONSE FACTOR 1; FAS LIGAND; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; GLUCOSE 6 PHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMAD7 PROTEIN; SMALL INTERFERING RNA; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GLOMERULONEPHRITIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MACROPHAGE; NONHUMAN; REVIEW; ULTRASOUND;

DEPENDOVIRUS; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NECROSIS; RNA, SMALL INTERFERING;

ANIMALIA; GLOMERULUS; PARVOVIRUS;

EID: 3042599052     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.919     Document Type: Review

References (52)

1. LAI LW, MOECKEL GW, LIEN YHH: Kidney-targeted liposome-mediated gene transfer in mice. Gene Ther. (1997) 4:426-431.
2. LAI LW, CHAN DM, ERICKSON RP, HSU SJ, LIEN YHH: Correction of renal tubular acidosis in carbonic anhydrase ii-deficient mice with gene therapy. J. Clin. Invest. (1998) 101:1320-1325.
3. SWENSON KM, KE BB, WANG T et al.: Fas ligand gene transfer to renal allografts in rats - effects on allograft survival. Transplantation (1998) 65:155-160.
4. LIEN YHH, LAI LW: Gene therapy for renal disorders - what are the benefits for the elderly? Drugs Aging (2002) 19:553-560.
5. LIEN YHH, LAI LW: Renal gene transfer - nonviral approaches. Mol. Biotechnol. (2003) 24:283-294.
6. IMAI E: Gene therapy approach in renal disease in the 21st century: Nephrol. Dial. Transplant. (2001) 16:26-34.
7. HANSS B, BRUGGEMAN LA: Applications of gene therapy to kidney disease. Curr. Opin. Nephrol. Hypertens. (2003) 12:439-445.
8. TOMITA N, MORISHITA R, TOMITA T, OGIHARA T: Potential therapeutic applications of decoy oligonucleotides. Curr. Opin. Mol. Ther. (2002) 4:166-170.
9. JARAD G, SIMSKE JS, SEDOR JR, SCHELLING JR: Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. Curr. Opin. Nephrol. Hypertens. (2003) 12:415-421.
10. KHACHIGIAN LM: Dnazymes: cutting a path to a new class of therapeutics. Curr. Opin. Mol. Ther. (2002) 4:119-121.
11. MCMANUS MT, SHARP PA: Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. (2002) 3:737-747.
12. XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. (2002) 20:1006-1010.
13. NOIRI E, PERESLENI T, MILLER F, GOLIGORSKY MS: In vivo targeting of inducible no synthase with oligodeoxynucleotides protects rat kidney against ischemia. J. Clin. Invest. (1996) 97:2377-2383.
14. HALLER H, DRAGUN D, MIETHKE A et al.: Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int. (1996) 50:473-480.
15. DAI CS, YANG JW, LIU YH: Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. J. Am. Soc. Nephrol. (2002) 13:411-422. Good experimental paper on HGF-based gene therapy for renal failure.
16. LIU YH, TOLBERT EM, LIN L et al.: Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int. (1999) 55:442-453.
17. FURUICHI K, WADA T, IWATA Y et al.: Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. (2003) 14:1066-1071.
18. AKAGI Y, ISAKA Y, ARAI M et al.: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extrallular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1996) 50:148-155.
19. MAESHIMA Y, KASHIHARA N, YASUDA T et al.: Inhibition of mesangial cell proliferation by E2f decoy oligodeoxynucleotide in vitro and in vivo. J. Clin. Invest. (1998) 101:2589-2597.
20. ISAKA Y, BREES DK, IKEGAYA K et al.: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. (1996) 2(4):418-423.
21. ISAKA Y, AKAGI Y, ANDO Y et al.: Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1999) 55:465-475.
22. ZHOU AH, UENO H, SHIMOMURA M et al.: Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-gbm nephritis. Kidney Int. (2003) 64:92-101.
23. GEHL J: Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand (2003) 177:437-447.
24. NAKAMURA H, ISAKA Y, TSUJIE M et al.: Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int. (2001) 59:2134-2145. Good experimental paper on electroporation- mediated gene therapy for glomerulonephritis.
25. TOMITA N, MORISHITA R, LAN HY et al.: In vivo administration of a nuclear transcription factor-kappa b decoy suppresses experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2000) 11:1244-1252.
26. KLUTH DC, AINSLIE CV, PEARCE WP et al.: Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J. Immunol. (2001) 166:4728-4736. Good experimental paper on macrophage-based gene therapy for glomerulonephritis.
27. WILSON HM, STEWART KN, BROWN PA et al.: Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. Mol. Ther. (2002) 6:710-717.
28. WILSON HM, KLUTH DC: Targeting genetically modified macrophages to the glomerulus. Nephron Exp. Nephrol. (2003) 94:E113-E118.
29. MUNGER KA, MONTERO A, FUKUNAGA M et al.: Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA (1999) 96:13375-13380.
30. HIGUCHI N, MARUYAMA H, KURODA T et al.: Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in wistar-kyoto rats. Gene Ther. (2003) 10:1297-1310.
31. CHOI YK, KIM YJ, PARK HS et al.: Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney. Gene Ther. (2003) 10:559-568.
32. ISAKA Y, AKAGI Y, ANDO Y, IMAI E: Application of gene therapy to diabetic nephropathy. Kidney Int. (1997) 60:S100-S103.
33. AHN JD, MORISHITA R, KANEDA Y et al.: Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther. (2004) 11(11):916-923.
34. TERADA Y, HANADA S, NAKAO A, KUWAHARA M, SASAKI S, MARUMO F: Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. (2002) 61:94-98.
35. LAN HY, MU W, TOMITA N et al.: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat uuo model. J. Am. Soc. Nephrol. (2003) 14:1535-1548. Good experimental paper on microbubble/ultrasound-based gene therepy for renal fibrosis.
36. NAKAMURA H, ISAKA Y, TSUJIE M et al.: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial alpha-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (uuo) rats. Gene Ther. (2002) 9:495-502.
37. YANG J, DAI C, LIU Y: Systemic administration of naked plasmid encoding heparocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. (2001) 8:1470-1479.
38. GAO XJ, MAE H, AYABE N et al.: Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int. (2002) 62:1238-1248.
39. YANG JW, DAI CS, LIU YH: Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J. Am. Soc. Nephrol. (2002) 13:2464-2477.
40. STEPKOWSKI SM, WANG ME, CONDON TP et al.: Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation (1998) 66:699-707.
41. VOS IH, GOVERS R, GRONE HJ et al.: NF kappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. (2000) 14:815-822.
42. AZUMA H, TOMITA N, KANEDA Y et al.: Transfection of nf kappa b-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther. (2003) 10:415-425.
43. TOMASONI S, AZZOLLINI N, CASIRAGHI F et al.: CTLA-4-Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J. Am. Soc. Nephrol. (2000) 11:747-752.
44. SONNTAG KC, EMERY DW, YASUMOTO A et al.: Tolerance to solid organ transplants through transfer of MHC class II genes. J. Clin. Invest. (2001) 107:65-71.
45. SUN MS, PAN CJ, SHIEH JJ et al.: Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice. Hum. Mol. Genet. (2002) 11:2155-2164.
46. PARK J, MURRAY GJ, LIMAYE A et al.: Long-term correction of globotriaosylceramide storage in fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc. Natl. Acad. Sci. USA (2003) 100:3450-3454. Good experimental paper showing long-term effect of AAV-based gene therapy for Fabry mice.
47. IDENO J, MIZUKAMI H, HONDA K et al.: Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in brattleboro rats. Mol. Ther. (2003) 8:895-902. Good experimental paper on AAV-based gene therapy for central diabetes insipidus, with interesting result from physiological studies.
48. ST GEORGE JA: Gene therapy progress and prospects: adenoviral vectors. Gene Ther. (2003) 10:1135-1141. Excellent review on adenoviral vectors.
49. TENENBAUM L, LEHTONEN E, MONAHAN PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. (2003) 3:545-565.
50. DONSANTE A, VOGLER C, MUZYCZKA N et al.: Observed incidence of tumorigenesis in long-term rodent studies of raav vectors. Gene Ther. (2001) 8:1343-1346.
51. PACHORI AS, MELO LG, ZHANG LN et al.: Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem. Biophys. Res. Commun. (2004) 313:528-533.
52. NIIDOME T, HUANG L: Gene therapy progress and prospects: nonviral vectors. Gene Ther. (2002) 9:1647-1652.